<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01208376</url>
  </required_header>
  <id_info>
    <org_study_id>SHCS 625</org_study_id>
    <nct_id>NCT01208376</nct_id>
  </id_info>
  <brief_title>Prevalence of Liver Fibrosis and Progression of Liver Fibrosis</brief_title>
  <official_title>Prevalence of Liver Fibrosis and Progression of Liver Fibrosis in HIV-infected, Hepatitis C (HCV) and Hepatitis B (HBV) Seronegative Patients With Chronic Alanine Aminotransferase (ALT) Elevation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helen Kovari-Kramer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss HIV Cohort Study</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Little is known about the clinical significance of chronic alanine aminotransferase (ALT)
      elevation in HIV-infected patients without hepatitis B and C coinfection. Study aim is first
      to evaluate the prevalence of liver fibrosis and cirrhosis in HIV-infected patients with
      chronic ALT elevation and no chronic viral hepatitis using non-invasive diagnostic tests and
      second to find associated factors with significant fibrosis and cirrhosis. In a second
      longitudinal part we intend to assess fibrosis progression within 1 and 3 years.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Liverfibrosis</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">195</enrollment>
  <condition>HIV Infection and Chronic Alanine Aminotransferase Elevation</condition>
  <arm_group>
    <arm_group_label>unexplained chronic ALT elevation</arm_group_label>
    <description>Case patients: HIV-infected, unexplained chronic alanine aminotransferase (ALT) elevation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>always normal ALT</arm_group_label>
    <description>Control patients: HIV-infected, always normal ALT values</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fibroscan</intervention_name>
    <description>Fibroscan and Serum Fibrose-marker</description>
    <arm_group_label>unexplained chronic ALT elevation</arm_group_label>
    <arm_group_label>always normal ALT</arm_group_label>
    <other_name>Fibroscan and Serum Fibrose-marker</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected, hepatitis B and C seronegative Patients With Chronic alanine aminotransferase
        (ALT) Elevation
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria: Case patients:

          -  HIV-1 infection

          -  no hepatitis B and C coinfection

          -  chronic alanine aminotransferase (ALT) elevation after 1.1.2007

          -  signed informed consent

          -  no other common cause of liver disease

        Control patients:

          -  HIV-infection

          -  no hepatitis B and C coinfection

          -  no ALT elevation after 1.1.2002, the date when ALT values were regularly collected in
             the Swiss HIV Cohort Study (SHCS)

          -  no known chronic liver disease

        Exclusion criteria: please see inclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>01 Studienregister MasterAdmins</last_name>
    <role>Study Director</role>
    <affiliation>UniversitaetsSpital Zuerich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2010</study_first_submitted>
  <study_first_submitted_qc>September 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2010</study_first_posted>
  <last_update_submitted>December 19, 2016</last_update_submitted>
  <last_update_submitted_qc>December 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Helen Kovari-Kramer</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

